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The chemistry of natural nucleosides and their analogues has been widely studied 
due to their potential as fungicidal, antitumor, and antiviral agents.
1
  Consequently, 
extensive modifications have been made to both the heterocyclic base and the sugar 
moiety in order to avoid the drawbacks shown by nucleosides or analogues in certain 
applications. 
For organic chemists, enzymatic-catalyzed reactions have become standard 
procedures for nucleoside modification, since they avoid the time-consuming protection 
and deprotection steps required by the occurrence of various hydroxyl groups in the sugar 
skeleton of the natural nucleosides.
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The 3’,5’-diamino analogues of thymidine
3
 and 2’-deoxyuridine
4
 have been 
synthesized previously, and they showed a complete lack of either antiviral or 
antineoplastic activity.  It is known that in some cases a simple acylation of one of the 
hydroxyl groups in a nucleoside can result in an increase of their biological activity 
compared with the unmodified derivative.
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Regioselective protection of one of the primary amino groups situated in the 3’- or 5’- 
positions is a very difficult task, since traditional chemical methods do not distinguish 
between them and, moreover, there are other reactive points on the molecule such as the 
nitrogen atoms on the bases. 
It is the purpose of this paper to report the regioselective enzymatic acylation of the 
amino groups in the sugar moiety of pyrimidine 3’,5’-diaminonucleosides, as well as to 
show improved syntheses of the starting materials, 3’,5’-diamino-3’,5’-dideoxythymidine 
and 3’,5’-diamino-2’,3’,5’-trideoxyuridine, on the basis of its fewer steps and high overall 
yields. 
Treatment of thymidine (1) with methanesulfonyl chloride in pyridine at 0 ˚C afforded 
the disulfonate 3 (Scheme 1).  When this dimesyl derivative was heated under reflux with 
an excess of Et3N in EtOH solution, anhydronucleoside 5 was isolated in 86% yield.  The 
diazido derivative 7 was obtained by treatment of 5 with sodium azide in DMF solution at 
130 ˚C.  Hydrogenation of 7 in EtOH in the presence of 10% Pd/C afforded 3’,5’-diamino-
3’,5’-dideoxythymidine (9), through a four-step sequence with 63% overall yield. 
The same strategy was applied to prepare 3’,5’-diamino-2’,3’,5’-trideoxyuridine (10).  
In this case, nucleophilic displacement with NaN3 on anhydronucleoside 6 was carried out 
at 120 ˚C, since higher reaction temperatures gave decomposition products and lower 
ones provided just 5’-OMs displacement without anhydronucleoside opening.  In spite of 
moderate yield of this step, we obtained diamino nucleoside 10 in four steps with 41% 
overall yield, almost double that described in the literature.
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We have previously reported that oxime esters are good acylating agents in 
regioselective enzymatic acylations of nucleosides.
6
  Since amines are much more 
nucleophilic than alcohols, they react non-enzymatically with oxime esters.  To solve this 
problem, non-activated esters, such as alkyl esters, were used.  The studies of enzymatic 
acylation focused on 3’,5’-diamino-3’,5’-dideoxythymidine (9, Scheme 2). 
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The reaction was carried out with 8 equivalents of ethyl acetate in THF at 40 ˚C in 
the presence of molecular sieves (4Å) to avoid decomposition of the starting material 
(entry 1, Table 1).  Among the enzymes tested [Candida antarctica lipase B (CAL-B), 
Pseudomonas cepacia lipase (PSL), immobilized Pseudomonas cepacia lipase (PSL-C), 
Candida rugosa lipase (CRL), and Subtilisin], CAL-B showed excellent regioselectivity 
towards the 5’-NH2, 11b being isolated with 80% yield after flash chromatography column.  
The structure of this compound is clearly ascertained from its 
1
H NMR (MeOH-d4) 
spectrum, which showed a downfield shift corresponding to both H5’ protons from 2.89-
3.23 ppm in diaminonucleoside 9 to 3.72 ppm in 11b.  Meanwhile, H3’ did not display any 
significant change.  In addition, heteronuclear correlation 
1
H-
13
C experiment 2D HMBC 
showed a cross-peak between H5’ and C=O, which corresponds to correlation H5’-C-N-CO 
via 
3
JCH.  It is noteworthy that no N-3’ acylated derivative 13b was formed, in spite of both 
amino groups being primary.  Diacetylated derivative 15b (Chart) was detected as a minor 
product (5%).  In order to minimize the formation of this compound, the process was 
carried out at 28 ˚C.  However, 20% of N-3’,5’ diacetylated 15b was obtained against our 
expectations (entry 2, Table 1). 
In an attempt to confer versatility to this enzymatic reaction, other acyl moieties, such 
as formyl, alkyl, alkenyl, or aryl, were introduced.  Thus, only 2 equivalents of the more 
reactive ethyl formate were necessary to acylate compound 9.  Due to its higher reactivity, 
a lower yield of N-5’ formyl 11a was found, in addition to a considerable amount of N-3’,5’ 
diformyl 15a (entry 3, Table 1).  In contrast, complete regioselectivity towards the N-5’ 
position was achieved with high yield when ethyl butyrate, methyl crotonate, and methyl 
benzoate were employed (entries 46, Table 1).  In these cases, due to the lower 
reactivity of the esters, the ratios of acylating agents were increased.  Also, higher 
temperatures were used to bring conversions close to 100%. 
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Interestingly, PSL-C catalyzed the acetylation of 9 with total regioselectivity towards 
the N-3’ position.  Fifty equivalents of EtOAc and 60 ˚C were necessary to afford 
compound 13b with excellent yield (entry 8, Table 1).  The 
1
H NMR (D2O) spectrum, of 
this monoacylnucleoside presents a downfield shift of ca. 1 ppm on the H3’ proton (from 
3.34 ppm in 9 to 4.35 ppm in 13b), whereas H5’ almost did not change.  Moreover, it was 
possible to confirm the structure by 2D HMBC that showed a cross-peak between H3’ and 
C=O corresponding to correlation H3’-C-N-CO via 
3
JCH.  Lower temperatures and a lesser 
amount of acylating agent led to the recovery of a substantial quantity of unreacted 
starting material (entry 7, Table 1). 
On the other hand, when ethyl formate or butyrate were used, the process took place 
with lower selectivity (entries 910, Table 1).  In the cases of methyl crotonate or 
benzoate, which have already shown low reactivity with CAL-B, the reaction did not occur. 
When similar processes were carried out with 2’-deoxyuridine derivative 10, parallel 
behavior was observed.  To favor solubility of the starting nucleoside, pyridine was added 
as co-solvent. CAL-B kept its excellent regioselectivity in the acylation of N-5’ position, 
isolating exclusively compounds 12, except in case of ethyl formate in which 20% of diacyl 
derivative 16a was obtained (entries 15, Table 2). 
In contrast, PSL-C showed only moderate regioselectivity towards N-3’ in the case of 
acetylation (entry 6, Table 2) with an isolated yield of 61% for compound 14b.  The 
formylation occurred with no selectivity and the main product was the N-3’,5’ diformyl 
nucleoside derivative 16a (entry 7, Table 2).  Although ethyl butyrate presented a degree 
of selectivity towards N-3’, the conversion of the process was low even with prolonged 
reaction times (entry 8, Table 2). 
This enzymatic strategy allowed us to regioselectively synthesize, for the first time, 
N-3’ or N-5’ acylated pyrimidine 3’,5’-diamino nucleoside derivatives by means of a very 
simple and convenient procedure using PSL-C or CAL-B as biocatalysts, respectively.  
 5 
Moreover, an improved synthesis of pyrimidine 3’,5’-diamino-2’,3’,5’-trideoxynucleosides 
has been described through a four-step sequence and with high overall yield.  A series of 
N-monoacylated 3’,5’-diamino nucleosides was prepared as potential antiviral and/or 
antitumor agents.  The biological activity of these derivatives will be tested and the results 
will be reported in a due course. 
Experimental Section
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General.  Candida antarctica lipase B (CAL-B, 7300 PLU/g) was a gift from Novo 
Nordisk Co.  Immobilized Pseudomonas cepacia lipase (PSL-C, 783 U/g) was purchased 
from Amano Pharmaceutical Co. 
General Procedure for the Enzymatic Acylation of 3’,5’-Diaminonucleosides.  
Corresponding ester (ethyl formate, ethyl acetate, ethyl butyrate, methyl crotonate, and 
methyl benzoate) was added to a suspension of diaminonucleoside (20 mg, 0.08 mmol, in 
the case of 10 it was previously dissolved in 1 mL of dry pyridine), lipase (10 mg of CAL-B 
or 130 mg of PSL-C), and molecular sieves 4Å (20 mg) in dry THF (4.5 mL) under 
nitrogen, and the mixture was stirred at 250 rpm (temperature and reaction time are 
indicated in Table 1 and Table 2).  Then, the enzyme and molecular sieves were filtered 
off and washed with MeOH (35 mL).  The filtrate was evaporated to dryness and the 
crude residue was purified by flash chromatography column (gradient eluent 10% 
MeOH/EtOAcMeOH for compounds 11ae, 12ae and gradient eluent 10% 
MeOH/EtOAcMeOH10% NH3(aq.)/MeOH for compounds 13ac, 14ac). 
3’-Amino-5’-formylamino-3’,5’-dideoxythymidine (11a).  
1
H-NMR (MeOH-d4, 300 
MHz):    2.09 (s, 3H, H7), 2.32-2.55 (m, 2H, H2’), 3.55 (m, 1H, H3’), 3.76 (m, 2H, H5’), 3.90 
(m, 1H, H4’), 6.33 (dd, 1H, H1’, 
3
JHH 7.1, 
3
JHH 4.8 Hz), 7.68 (s, 1H, H6), and 8.33 (s, 1H, 
HCO);  MS (ESI
+
, m/z):  291 [(M+Na)
+
, 100%], and 269 [(M+H)
+
, 76]. 
 6 
5’-Acetylamino-3’-amino-3’,5’-dideoxythymidine (11b).  
1
H-NMR (MeOH-d4, 200 
MHz):    2.09 (s, 3H, H7), 2.15 (s, 3H, MeCO), 2.30-2.60 (m, 2H, H2’), 3.55 (m, 1H, H3’), 
3.72 (m, 2H, H5’), 3.88 (m, 1H, H4’), 6.30 (dd, 1H, H1’, 
3
JHH 7.3, 
3
JHH 4.8 Hz), and 7.68 (s, 
1H, H6);  MS (FAB
+
, m/z):  283 [(M+H)
+
, 15%], 245 (4), 180 (14), and 140 (47). 
3’-Amino-5’-butirylamino-3’,5’-dideoxythymidine (11c).  
1
H-NMR (MeOH-d4, 200 
MHz):    1.14 (t, 3H, H4’’, 
3
JHH 7.3 Hz), 1.83 (m, 2H, H3’’), 2.09 (s, 3H, H7), 2.30-2.57 (m, 
4H, H2’+H2’’), 3.55 (m, 1H, H3’), 3.70 (m, 2H, H5’), 3.87 (m, 1H, H4’), 6.30 (dd, 1H, H1’, 
3
JHH 
7.0, 
3
JHH 4.8 Hz), and 7.65 (s, 1H, H6);  MS (ESI
+
, m/z):  333 [(M+Na)
+
, 82%], and 311 
[(M+H)
+
, 100). 
3’-Amino-5’-crothonylamino-3’,5’-dideoxythymidine (11d).  
1
H-NMR (MeOH-d4, 
300 MHz):    2.05 (m, 6H, H4’’+H7), 2.33-2.53 (m, 2H, H2’), 3.55 (m, 1H, H3’), 3.79 (m, 2H, 
H5’), 3.90 (m, 1H, H4’), 6.17 (dq, 1H, H2’’, 
3
JHH 15.1, 
4
JHH 1.4 Hz), 6.29 (dd, 1H, H1’, 
3
JHH 7.1, 
3
JHH 4.3 Hz), 7.01 (dq, 1H, H3’’, 
3
JHH 15.1, 
3
JHH 6.8 Hz), and 7.64 (s, 1H, H6);  MS (ESI
+
, 
m/z):  331 [(M+Na)
+
, 100%], and 309 [(M+H)
+
, 75]. 
3’-Amino-5’-benzoylamino-3’,5’-dideoxythymidine (11e).  
1
H-NMR (MeOH-d4, 300 
MHz):    1.90 (s, 3H, H7), 2.37-2.57 (m, 2H, H2’), 3.62 (m, 1H, H3’), 3.95 (m, 1H, H4’), 4.02 
(m, 2H, H5’), 6.31 (dd, 1H, H1’, 
3
JHH 7.4, 
3
JHH 4.3 Hz), 7.63-7.77 (m, 4H, H6+Hm+Hp), and 
8.05 (m, 2H, Ho);  MS (ESI
+
, m/z):  383 [(M+K)
+
, 7%], 367 [(M+Na)
+
, 100], and 345 
[(M+H)
+
, 94]. 
3’-Amino-5’-formylamino-2’,3’,5’-trideoxyuridine (12a).  
1
H-NMR (MeOH-d4, 300 
MHz):    2.35-2.55 (m, 2H, H2’), 3.50 (m, 1H, H3’), 3.77 (m, 2H, H5’), 3.92 (m, 1H, H4’), 
5.90 (d, 1H, H5, 
3
JHH 8.0 Hz), 6.29 (dd, 1H, H1’, 
3
JHH 7.1, 
3
JHH 4.6 Hz), 7.88 (d, 1H, H6, 
3
JHH 
8.0 Hz), and 8.32 (s, 1H, HCO);  MS (ESI
+
, m/z):  293 [(M+K)
+
, 12%], 277 [(M+Na)
+
, 100], 
and 255 [(M+H)
+
, 77]. 
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5’-Acetylamino-3’-amino-2’,3’,5’-trideoxyuridine (12b).  
1
H-NMR (MeOH-d4, 200 
MHz):    2.16 (s, 3H, MeCO), 2.30-2.60 (m, 2H, H2’), 3.50 (m, 1H, H3’), 3.70 (m, 2H, H5’), 
3.90 (m, 1H, H4’), 5.90 (d, 1H, H5, 
3
JHH 7.9 Hz), 6.29 (dd, 1H, H1’, 
3
JHH 7.0, 
3
JHH 4.8 Hz), 
and 7.89 (d, 1H, H6, 
3
JHH 7.9 Hz);  MS (ESI
+
, m/z):  291 [(M+Na)
+
, 100%], and 269 
[(M+H)
+
, 73). 
3’-Amino-5’-butirylamino-2’,3’,5’-trideoxyuridine (12c).  
1
H-NMR (MeOH-d4, 300 
MHz):    1.14 (t, 3H, H4’’, 
3
JHH 7.4 Hz), 1.83 (m, 2H, H3’’), 2.35-2.55 (m, 4H, H2’+H2’’), 3.50 
(m, 1H, H3’), 3.71 (m, 2H, H5’), 3.90 (m, 1H, H4’), 5.89 (d, 1H, H5, 
3
JHH 8.0 Hz), 6.28 (dd, 
1H, H1’, 
3
JHH 7.4, 
3
JHH 4.6 Hz), and 7.91 (d, 1H, H6, 
3
JHH 8.0 Hz);  MS (ESI
+
, m/z):  319 
[(M+Na)
+
, 100%], and 297 [(M+H)
+
, 71]. 
3’-Amino-5’-crothonylamino-2’,3’,5’-trideoxyuridine (12d).  
1
H-NMR (MeOH-d4, 
300 MHz):    2.05 (dd, 3H, H4’’, 
3
JHH 6.8, 
4
JHH 1.7 Hz), 2.35-2.55 (m, 2H, H2’), 3.50 (m, 1H, 
H3’), 3.75 (m, 2H, H5’), 3.92 (m, 1H, H4’), 5.87 (d, 1H, H5, 
3
JHH 8.0 Hz), 6.16 (dq, 1H, H2’’, 
3
JHH 15.1, 
4
JHH 1.7 Hz), 6.28 (dd, 1H, H1’, 
3
JHH 7.1, 
3
JHH 4.6 Hz), 7.00 (dq, 1H, H3’’, 
3
JHH 
15.1, 
3
JHH 6.8 Hz), and 7.87 (d, 1H, H6, 
3
JHH 8.0 Hz);  MS (ESI
+
, m/z):  317 [(M+Na)
+
, 
100%], and 295 [(M+H)
+
, 50]. 
3’-Amino-5’-benzoylamino-2’,3’,5’-trideoxyuridine (12e).  
1
H-NMR (MeOH-d4, 300 
MHz):    2.39-2.59 (m, 2H, H2’), 3.59 (m, 1H, H3’), 3.93 (m, 2H, H5’), 4.03 (m, 1H, H4’), 
5.79 (d, 1H, H5, 
3
JHH 8.0 Hz), 6.29 (dd, 1H, H1’, 
3
JHH 7.1, 
3
JHH 4.0 Hz), 7.63-7.77 (m, 3H, 
Hm+Hp), 7.94 (d, 1H, H6, 
3
JHH 8.0 Hz), and 8.05 (m, 2H, Ho);  MS (ESI
+
, m/z):  369 [(M+K)
+
, 
15%], 353 [(M+Na)
+
, 100], and 331 [(M+H)
+
, 97]. 
5’-Amino-3’-formylamino-3’,5’-dideoxythymidine (13a).  
1
H-NMR (D2O, 200 MHz):  
  1.70 (s, 3H, H7), 2.25-2.50 (m, 2H, H2’), 3.04-3.29 (m, 2H, H5’), 3.92 (m, 1H, H4’), 4.42 
(m, 1H, H3’), 5.97 (dd, 1H, H1’, 
3
JHH 7.9, 
3
JHH 4.7 Hz), 7.31 (s, 1H, H6), and 7.92 (s, 1H, 
HCO);  MS (ESI
+
, m/z):  291 [(M+Na)
+
, 2%], and 269 [(M+H)
+
, 100]. 
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3’-Acetylamino-5’-amino-3’,5’-dideoxythymidine (13b).  
1
H-NMR (D2O, 300 MHz):  
  1.77 (s, 3H, H7), 1.90 (s, 3H, MeCO), 2.31-2.52 (m, 2H, H2’), 3.12-3.33 (m, 2H, H5’), 
3.99 (m, 1H, H4’), 4.35 (m, 1H, H3’), 6.04 (dd, 1H, H1’, 
3
JHH 7.7, 
3
JHH 5.1 Hz), and 7.38 (s, 
1H, H6);  MS (ES
+
, m/z):  283 (M
+
, 100%), 241 (4), 158 (23), 99 (17), and 60 (21);  MS 
(ESI
+
, m/z):  283 [(M+H)
+
, 100%]. 
5’-Amino-3’-butirylamino-3’,5’-dideoxythymidine (13c).  
1
H-NMR (MeOH-d4, 300 
MHz):    1.14 (t, 3H, H4’’, 
3
JHH 7.4 Hz), 1.83 (m, 2H, H3’’), 2.10 (s, 3H, H7), 2.38 (t, 2H, H2’’, 
3
JHH 7.1 Hz), 2.42-2.64 (m, 2H, H2’), 3.02-3.17 (m, 2H, H5’), 3.91 (m, 1H, H4’), 4.58 (m, 1H, 
H3’), 6.37 (dd, 1H, H1’, 
3
JHH 7.1, 
3
JHH 5.7 Hz), and 7.75 (s, 1H, H6);  MS (ESI
+
, m/z):  349 
[(M+K)
+
, 15%], 333 [(M+Na)
+
, 33], and 311 [(M+H)
+
, 100]. 
5’-Amino-3’-formylamino-2’,3’,5’-trideoxyuridine (14a).   
1
H-NMR (D2O, 300 MHz):  
  2.52-2.73 (m, 2H, H2’), 3.29-3.49 (m, 2H, H5’), 4.16 (m, 1H, H4’), 4.61 (m, 1H, H3’), 5.91 
(d, 1H, H5, 
3
JHH 8.3 Hz), 6.18 (dd, 1H, H1’, 
3
JHH 7.7, 
3
JHH 5.1 Hz), 7.74 (d, 1H, H6, 
3
JHH 8.3 
Hz), and 8.15 (s, 1H, HCO);  MS (ESI
+
, m/z):  277 [(M+Na)
+
, 5%], and 255 [(M+H)
+
, 100]. 
3’-Acetylamino-5’-amino-2’,3’,5’-trideoxyuridine (14b).  
1
H-NMR (D2O, 300 MHz):  
  1.89 (s, 3H, MeCO), 2.29-2.53 (m, 2H, H2’), 3.07-3.26 (m, 2H, H5’), 3.96 (m, 1H, H4’), 
4.33 (m, 1H, H3’), 5.75 (d, 1H, H5, 
3
JHH 8.3 Hz), 6.03 (dd, 1H, H1’, 
3
JHH 7.7, 
3
JHH 5.4 Hz), 
and 7.58 (d, 1H, H6, 
3
JHH 8.3 Hz);  MS (ESI
+
, m/z):  291 [(M+Na)
+
, 3%], and 269 [(M+H)
+
, 
100]. 
5’-Amino-3’-butirylamino-2’,3’,5’-trideoxyuridine (14c).  
1
H-NMR (D2O, 300 MHz):  
  0.89 (t, 3H, H4’’, 
3
JHH 7.4 Hz), 1.60 (m, 2H, H3’’), 2.24 (t, 2H, H2’’, 
3
JHH 7.4 Hz), 2.40-2.68 
(m, 2H, H2’), 3.23-3.42 (m, 2H, H5’), 4.10 (m, 1H, H4’), 4.48 (m, 1H, H3’), 5.87 (d, 1H, H5, 
3
JHH 8.0 Hz), 6.14 (dd, 1H, H1’, 
3
JHH 6.2, 
3
JHH 5.1 Hz), and 7.70 (d, 1H, H6, 
3
JHH 8.0 Hz);  
MS (ESI
+
, m/z):  319 [(M+Na)
+
, 7%], and 297 [(M+H)
+
, 100]. 
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3’,5’-Diformylamino-3’,5’-dideoxythymidine (15a).  
1
H-NMR (MeOH-d4, 300 MHz):  
  2.10 (s, 3H, H7), 2.47-2.70 (m, 2H, H2’), 3.65-3.89 (m, 2H, H5’), 4.11 (m, 1H, H4’), 4.62 
(m, 1H, H3’), 6.34 (dd, 1H, H1’, 
3
JHH 7.1), 7.73 (s, 1H, H6), 8.28 (s, 1H, HCO), and 8.31 (s, 
1H, HCO);  MS (ESI
+
, m/z):  335 [(M+K)
+
, 10%], 319 [(M+Na)
+
, 100], and 297 [(M+H)
+
, 1]. 
3’,5’-Diacetylamino-3’,5’-dideoxythymidine (15b).  
1
H-NMR (MeOH-d4, 300 MHz):  
  2.10 (s, 3H, H7), 2.16 (s, 6H, MeCO), 2.30-2.70 (m, 2H, H2’), 3.60-3.80 (m, 2H, H5’), 
4.05 (m, 1H, H4’), 4.50 (m, 1H, H3’), 6.32 (dd, 1H, H1’, 
3
JHH 6.9, 
3
JHH 6.0 Hz), and 7.70 (s, 
1H, H6);  MS (ESI
+
, m/z):  363 [(M+K)
+
, 11%], and 347 [(M+Na)
+
, 100]. 
3’,5’-Diformylamino-2’,3’,5’-trideoxyuridine (16a).  
1
H-NMR (MeOH-d4, 300 MHz):  
  2.53-2.70 (m, 2H, H2’), 3.62-3.90 (m, 2H, H5’), 4.11 (m, 1H, H4’), 4.61 (m, 1H, H3’), 5.92 
(d, 1H, H5, 
3
JHH 8.3 Hz), 6.33 (dd, 1H, H1’, 
3
JHH 7.1 Hz), 7.92 (d, 1H, H6, 
3
JHH 8.3 Hz), 8.29 
(s, 1H, HCO), and 8.30 (s, 1H, HCO);  MS (ESI
+
, m/z):  321 [(M+K)
+
, 10%], and 305 
[(M+Na)
+
, 100]. 
3’,5’-Diacetylamino-2’,3’,5’-trideoxyuridine (16b).  
1
H-NMR (MeOH-d4, 200 MHz):  
  2.16 (s, 6H, MeCO), 2.47-2.62 (m, 2H, H2’), 3.60-3.82 (m, 2H, H5’), 4.10 (m, 1H, H4’), 
4.51 (m, 1H, H3’), 5.92 (d, 1H, H5, 
3
JHH 8.3 Hz), 6.31 (dd, 1H, H1’, 
3
JHH 6.4 Hz), and 7.92 (d, 
1H, H6, 
3
JHH 8.3 Hz);  MS (ESI
+
, m/z):  349 [(M+K)
+
, 6%], and 333 [(M+Na)
+
, 100]. 
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